All News
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read ArticleBest of 2023: New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article![](https://pbs.twimg.com/media/GCUBSekWcAA222m.jpg)
![](https://pbs.twimg.com/media/GCTYIRwXIAAOfpc.jpg)
Links:
![](https://pbs.twimg.com/media/GCS8rHAXYAA4xlW.jpg)
Links:
![](https://pbs.twimg.com/media/GCSFv_DXEAApu7V.jpg)
![](https://pbs.twimg.com/media/GCJE89XXgAAJThw.jpg)
Links:
![](https://pbs.twimg.com/media/GCIpnZOXsAAoTWy.jpg)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Dr. John Cush RheumNow ( View Tweet)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Dr. John Cush RheumNow ( View Tweet)
![](https://pbs.twimg.com/media/GCD7UahWkAAgGJY.jpg)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Links:
Dr. John Cush RheumNow ( View Tweet)
![](https://pbs.twimg.com/media/GCDEpRmWMAAGWTP.jpg)
![](https://pbs.twimg.com/media/GB_2h8FW0AAADZl.jpg)
Links:
![](https://pbs.twimg.com/media/GB_bAPPWkAA6eAT.jpg)
![](https://pbs.twimg.com/media/GB_NO7NXsAAKga6.jpg)
![](https://pbs.twimg.com/media/GB-x81SXUAEHkqU.jpg)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Dr. John Cush RheumNow ( View Tweet)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Dr. John Cush RheumNow ( View Tweet)
![](/themes/custom/rheumnow_theme/assets/images/rheumnow_logo.png)
Links:
Dr. John Cush RheumNow ( View Tweet)